

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	David Spencer et al.	Examiner:	Qian Janice Li
Appln. No.:	10/781,384	Group Art Unit:	1633
Filed:	February 18, 2004	Docket:	BEL-2001-UT
Conf. No.:	2112		
Title:	INDUCED ACTIVATION IN DENDRITIC CELLS		

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam,

In compliance with the duty under 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the Examiner's attention for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form SB08A be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the SB08A form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

The listed documents are being submitted in compliance with 37 CFR § 1.97(b), after the mailing date of the first office action on the merits, but prior to the final office action. Accordingly, Applicants respectfully submit payment of \$180.00. If any additional fees are due, please contact the undersigned attorney at (858) 623-9470.

INFORMATION DISCLOSURE STATEMENT

Serial No.: 10/781,384

Filing Date: February 18, 2004

Title: INDUCED ACTIVATION IN DENDRITIC CELLS

Page 2

Dkt: BEI-2001-UT

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

Date: December 1, 2006

By: /Bruce Grant/

Bruce Grant

Reg. No. 47608

Attorney for Applicants

BioTechnology Law Group

Customer No. 47328

Telephone: (858) 623-9470

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/781,384
Filing Date	February 18, 2004
First Named Inventor	David Spencer
Group Art Unit	1633
Examiner Name	Qian Janice Li

Sheet 1 of 1

Attorney Docket No: BEL-2001-UT

US PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	US-6497876	10-29-1999	Maraskovsky, et al.	
	A2.	US-6558951	05-06-2003	Tomai, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
---------------------	-----------------------	---------------------	------------------	---	---	----------------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A3.	Goodwin, J.S., "Immunomodulation by eicosanoids and anti-inflammatory drugs," Curr Opin Immunol. 1989, Vol. 2, pp. 264-268	
	A4.	Hanks B.A., et al., "Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo" Nature Medicine, Vol. 11, No. 2, 2005 pp. 130-137	
	A5.	Hauer et al., "TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2 5-mediated activation of the noncanonical NF- B pathway by TRAF-binding TNFRs," PNAS, Vol. 102, No. 8, February 22, 2005, pp. 2874-2879	
	A6.	Kadowaki N., et al., "Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens," J Exp Med., 2001, Vol. 194, pp. 863-869	
	A7.	Kalinski P., et al., "Prostaglandin E2 is a selective inducer of human interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer," Blood, 2001 Vol. 97, pp. 3466-3469	
	A8.	Lapointe R., et al., "Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes," Eur J Immunol., 2000, Vol. 30, pp. 3291-3298	
	A9.	Luft T., et al., "Functionally distinct dendritic cells (DC) populations induced by physiologic stimuli: prostoglandin-producing E(2) regulates the migratory capacity of specific DC subsets," Blood, 2002 Vol. 100, pp. 1362-1372	
	A10.	Napolitani et al., "Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells," Nat Immunol. 2005 Aug; Vol. 6, No. 8, pp. 769-776	
	A11.	Rescigno M., et al., "Dendritic cell survival and maturation are regulated by different signaling pathways," J Exp Med., 1998, Vol. 188, pp. 2175-2180	
	A12.	Scandella E., et al., "Prostaglandin E2 is a key factor of CCR7 surface expression and migration of monocyte-derived dendritic cells," Blood, 2002, Vol. 100 pp. 1354-1361	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/781,384
Filing Date	February 18, 2004
First Named Inventor	David Spencer
Group Art Unit	1633
Examiner Name	Qian Janice Li

Sheet 2 of 2

Attorney Docket No: BEL-2001-UT

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A13.	Spencer D.M., et al., "Controlling signal transduction with synthetic ligands," Science, November 12, 1993, Vol. 262 No. 5136, pp. 1019-1024	
	A14.	Tai et al., "Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications," Cancer Research, April 15, 2004, Vol. 64, pp. 2846-2852	
	A15.	Tone M., et al., "Regulation of CD40 function by its isoforms generated through alternative splicing," PNAS, February 13, 2001, Vol. 98, No. 4, pp. 1751-1756	
	A16.	van der Pouw Krann T.C., et al., "Prostaglandin E2 is a potent inhibitor of human interleukin12 production," J Exp Med., 1995, Vol. 181, pp.775-779	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached